Stem cell firm opening raises questions
By Associated Press,
Associated Press
| 05. 01. 2008
A California-based stem cell research company will get $589,000 in state grants to open a New Jersey facility and create 12 new jobs, a plan questioned by those worried about the governor's proposed budget cuts.
"It does seem questionable to be writing checks to companies that are going to hire 12 people when you're cutting higher education and can't pay for transportation," said Jon Shure, president of the liberal-leaning New Jersey Policy Perspective that has criticized taxpayer-funded business incentives and tax breaks.
Democratic Gov. Jon S. Corzine, who joined officials from StemCyte and Rutgers University on Thursday to announce StemCyte's plan to open a facility in Ewing, defended the incentives.
"The addition of StemCyte to our portfolio of companies represents an important economic investment that brings with it the promise of discovery and cures for some of our most devastating diseases and injuries," Corzine said as he toured a Rutgers stem cell lab. "I am proud to welcome StemCyte to the Garden State."
The Ewing facility will house executive management and therapeutics team members, and serve as an East Coast...
Related Articles
By Carly Mallenbaum, Axios [cites Emily Galpern] | 03.29.2026
More Americans are turning to surrogacy to build their families, as the practice becomes more common and more publicly discussed.
Why it matters: As surrogacy becomes more visible and accessible, ethical, legal and cultural tensions become harder to ignore...
By Carly Mallenbaum, Axios [cites Surrogacy360] | 03.29.2026
Without a federal law, surrogacy in the U.S. is governed by a patchwork of state regulations/
Why it matters: Confusing, varied local rules can determine everything from whether agreements are legally binding to who is recognized as a parent at...
By David Jensen, The California Stem Cell Report | 03.26.2026
SACRAMENTO, Ca. -- California’s $12 billion stem cell and gene therapy program scored a historic first today, announcing that it had for the first time helped to finance a revolutionary treatment that will now be available to the general public...
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
